This Anthrax Edema Factor antibody is un-conjugated
Application
ELISA
Purification
Anthrax Edema Factor Antibody is affinity chromatography purified via peptide column.
Immunogen
Anthrax Edema Factor antibody was raised against a synthetic peptide corresponding to 16 amino acids near the carboxy terminus of the Anthrax edema factor protein. The immunogen is located within the last 50 amino acids of Anthrax Edema Factor.
Anthrax Edema Factor antibody can be used for the detection of Anthrax PA protein in ELISA. It will detect 10 ng of free peptide at 1 μ,g/mL.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Anthrax Edema Factor Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
Anthrax Edema Factor antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Anthrax Edema Factor Antibody: Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface, these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF, the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. EF is a calmodulin and Ca++-dependent adenylate cyclase responsible for the edema seen in the disease. It is thought to benefit the B. anthracis bacteria by inhibiting cells of the host immune system.